Teva is primed for a big bounce after years of underperformance, Barclays says

Published Tue, Apr 5 20228:44 AM EDT

A Teva Pharmaceutical Industries building is seen in Jerusalem December 14, 2017.

Ammar Awad | Reuters

Shares for Teva Pharmaceuticals could jump 31% from here after the company settles a spate of legal issues, according to Barclays.

More In Street Calls

Analysts name the top 'high conviction' stocks for playing the market turbulence

Here are Friday's biggest analyst calls: Apple, Tesla, Coinbase, Domino's, Costco, Meta & more

Wedbush upgrades fuboTV to outperform citing 'compelling entry point' after stock pullback